Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Zinger Key PointsShares of COVID-19 vaccine makers are trading lower Friday.Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths.Want to trade this news? Get access to the 34-0 income strategy that loves volatility →Shares of COVID-19 vaccine makersPfizer IncPFE,BioNTech SE ADRBNTXandModerna IncMRNAare trading lower Friday following aWashington Postreportthat Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine Adverse Event Reporting System.What To Know:The plan has alarmed career scientists, who note the vaccines have been extensively studied. According to the report, Trump officials will present the claim to an influential CDC advisory panel next week.Per the Washington Post, this panel, the Advisory Committee on Immunization Practices, is considering new, more restrictive vaccine recommendations. Its decisions are critical as they determine insurance coverage and pharmacy access to the shots.Future revenue for COVID-19 vaccine makers could be significantly impacted. The committee isweighingoptions such as recommending the vaccine only for those 75 and older or instructing younger individuals to consult a physician before vaccination.This potential narrowing of the market, driven by an administration critical of past vaccine policies, signals a major headwind for future sales.Benzinga Edge Rankings:Reflecting Friday’s negative pressure,Benzinga Edgerankings show Pfizer’s stock has a particularly weak Momentum score of just 19.96.Price Action:According to data fromBenzinga Pro, shares of BioNTech are trading lower by 8.20% at $95.87, Moderna lower by 8.05% at $23.34 and Pfizer down 3.98% at $23.88.Friday afternoon’s price action left Moderna trading just above its 52-week low of $23.15, while Pfizer and BioNTech hovered near their session lows of $23.93 and $90.12, respectively.Read Also:Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud CaseHow To Buy PFE StockBy now you're likely curious about how to participate in the market for Pfizer – be it to purchase shares, or even attempt to bet against the company.Buying shares is typically done through a brokerage account. You can find a list ofpossible trading platforms here.Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting astock can be found at this resource.Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.Loading...Loading...Read Next:Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 NextImage: ShutterstockBNTXBioNTech SE$95.61-8.34%Stock Score Locked: Edge Members OnlyBenzinga Rankings give you vital metrics on any stock – anytime.Unlock RankingsEdge RankingsMomentum38.11GrowthN/AQuality77.18ValueN/APrice TrendShortMediumLongOverviewMRNAModerna Inc$23.50-7.42%PFEPfizer Inc$23.93-3.76%This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .Posted In:Newswhy it's moving